{"id":"zebinix","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Eslicarbazepine acetate (ESL)"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Sodium channel alpha subunit"},"_scrapedAt":"2026-03-28T02:58:59.520Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Partial seizure","diseaseId":"partial-seizure","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06597084","phase":"PHASE2","title":"Anti-epileptogenic Effects of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2019-05-29","conditions":"Post Stroke Epilepsy","enrollment":129},{"nctId":"NCT02283814","phase":"PHASE1","title":"A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-01","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT02283788","phase":"PHASE1","title":"Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-03","conditions":"Epilepsy","enrollment":67},{"nctId":"NCT01879345","phase":"PHASE1","title":"A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-10","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02281591","phase":"PHASE1","title":"Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-06","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT01679002","phase":"PHASE1","title":"Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2003-10","conditions":"Epilepsy","enrollment":12},{"nctId":"NCT02172742","phase":"PHASE1","title":"The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-05","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT00957047","phase":"PHASE3","title":"Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Partial Epilepsy","enrollment":395},{"nctId":"NCT00957684","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-07","conditions":"Refractory Partial Epilepsy","enrollment":402},{"nctId":"NCT00988429","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-12-02","conditions":"Partial Epilepsy","enrollment":653},{"nctId":"NCT02520557","phase":"","title":"An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate","status":"TERMINATED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-11-30","conditions":"SCAR","enrollment":121},{"nctId":"NCT03116828","phase":"PHASE4","title":"A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-07-07","conditions":"Epilepsy With Partial On-set Seizures","enrollment":102},{"nctId":"NCT04221282","phase":"","title":"ZEBinix® Retention Rate in Epilepsy in Elderly Patients","status":"UNKNOWN","sponsor":"Centre Hospitalier Saint Joseph Saint Luc de Lyon","startDate":"2019-04-01","conditions":"Epilepsy, Aging Disorder, Aging","enrollment":50},{"nctId":"NCT04095182","phase":"PHASE1","title":"Clinical Trial for Zebinix (Eslicarbazepine Acetate) in Healthy Korean and Caucasian Adult","status":"COMPLETED","sponsor":"Whanin Pharmaceutical Company","startDate":"2019-08-22","conditions":"Partial-onset Seizures With or Without Secondary Generalisation","enrollment":50},{"nctId":"NCT03082222","phase":"","title":"ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions","status":"COMPLETED","sponsor":"Eisai GmbH","startDate":"2015-07","conditions":"Focal Epilepsy","enrollment":246},{"nctId":"NCT02912364","phase":"PHASE4","title":"Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults","status":"COMPLETED","sponsor":"Stanford University","startDate":"2016-07","conditions":"Epilepsy","enrollment":46},{"nctId":"NCT00988156","phase":"PHASE3","title":"Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-12-07","conditions":"Partial Epilepsy in Children and Adolescents","enrollment":304},{"nctId":"NCT02484001","phase":"PHASE3","title":"Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2016-03-01","conditions":"Epilepsy","enrollment":206},{"nctId":"NCT00910247","phase":"PHASE3","title":"Eslicarbazepine Acetate Monotherapy Long Term Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-08","conditions":"Epilepsy","enrollment":274},{"nctId":"NCT02491073","phase":"","title":"Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-09","conditions":"Epilepsy","enrollment":71},{"nctId":"NCT03108729","phase":"PHASE3","title":"A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug","status":"WITHDRAWN","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-07-06","conditions":"Epilepsy","enrollment":""},{"nctId":"NCT02170064","phase":"PHASE2","title":"Pharmacokinetics, Efficacy and Tolerability of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-06","conditions":"Epilepsy","enrollment":35},{"nctId":"NCT02727101","phase":"PHASE4","title":"Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.","status":"TERMINATED","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2015-11","conditions":"Epilepsy","enrollment":8},{"nctId":"NCT02170077","phase":"PHASE2","title":"A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-04","conditions":"Epilepsy","enrollment":144},{"nctId":"NCT01422720","phase":"PHASE3","title":"Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-04","conditions":"Epilepsy","enrollment":72},{"nctId":"NCT02172755","phase":"PHASE1","title":"Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-06","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02170649","phase":"PHASE1","title":"The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-09","conditions":"Epilepsy","enrollment":12},{"nctId":"NCT03116321","phase":"PHASE1","title":"Bioequivalence of Two Different Sources of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2016-12-03","conditions":"Epilepsy","enrollment":24},{"nctId":"NCT01532726","phase":"","title":"Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2012-03","conditions":"Epilepsy","enrollment":56},{"nctId":"NCT01091662","phase":"PHASE3","title":"Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-06","conditions":"Epilepsy","enrollment":172},{"nctId":"NCT01162460","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-12","conditions":"Epilepsy","enrollment":815},{"nctId":"NCT02171195","phase":"PHASE1","title":"A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2000-07","conditions":"Epilepsy","enrollment":64},{"nctId":"NCT00980746","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-11","conditions":"Painful Diabetic Neuropathy","enrollment":557},{"nctId":"NCT02777671","phase":"PHASE1","title":"Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-10","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT00866775","phase":"PHASE3","title":"Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Epilepsy With Simple or Complex Partial Onset Seizures","enrollment":193},{"nctId":"NCT02556320","phase":"NA","title":"Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2013-05","conditions":"Epilepsy, Drug Hypersensitivity Syndrome","enrollment":30},{"nctId":"NCT02573272","phase":"","title":"Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors","status":"UNKNOWN","sponsor":"Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud","startDate":"2015-06","conditions":"Epilepsy","enrollment":204},{"nctId":"NCT01830400","phase":"","title":"A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2012-04","conditions":"Partial Onset Seizures","enrollment":254},{"nctId":"NCT00987558","phase":"PHASE1","title":"Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-06","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT02284880","phase":"PHASE1","title":"Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-10","conditions":"Epilepsy","enrollment":40},{"nctId":"NCT02281526","phase":"PHASE1","title":"An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-05","conditions":"Epilepsy","enrollment":17},{"nctId":"NCT02284854","phase":"PHASE1","title":"Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-07","conditions":"Epilepsy","enrollment":43},{"nctId":"NCT01678976","phase":"PHASE1","title":"Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-03","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT02288312","phase":"PHASE1","title":"Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-05","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02171234","phase":"PHASE1","title":"A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-02","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT02279667","phase":"PHASE1","title":"Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-02","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT02281422","phase":"PHASE1","title":"An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-03","conditions":"Epilepsy","enrollment":40},{"nctId":"NCT00900237","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetics and Tolerability of Multiple Doses of Eslicarbazepine Acetate and Oxcarbazepine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-11","conditions":"Partial Epilepsy","enrollment":14},{"nctId":"NCT01879332","phase":"PHASE1","title":"A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-12","conditions":"Epilepsy","enrollment":16},{"nctId":"NCT02283827","phase":"PHASE1","title":"Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-01","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT00971295","phase":"PHASE1","title":"Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Metformin in Healthy Volunteers","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-10","conditions":"Neuropathic Pain","enrollment":20},{"nctId":"NCT00898560","phase":"PHASE1","title":"Effect of Repeat Administration of Eslicarbazepine Acetate on the Pharmacokinetics of a Combined Oral Contraceptive","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2008-09","conditions":"Partial Epilepsy","enrollment":20},{"nctId":"NCT02284828","phase":"PHASE1","title":"Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-09","conditions":"Epilepsy","enrollment":26},{"nctId":"NCT02283840","phase":"PHASE1","title":"Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-05","conditions":"Epilepsy","enrollment":60},{"nctId":"NCT02281448","phase":"PHASE1","title":"Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-03","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT02287415","phase":"PHASE1","title":"The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2002-05","conditions":"Epilepsy","enrollment":13},{"nctId":"NCT02283801","phase":"PHASE1","title":"Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-11","conditions":"Epilepsy","enrollment":32},{"nctId":"NCT00981227","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2007-11","conditions":"Postherpetic Neuralgia","enrollment":567},{"nctId":"NCT01527513","phase":"PHASE2","title":"Effects of Eslicarbazepine Acetate (Esl, Bia 2-093) on Cognitive Function in Children With Partial Onset Seizures","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2010-08","conditions":"Partial Epilepsy","enrollment":123},{"nctId":"NCT01129960","phase":"PHASE3","title":"Eslicarbazepine Acetate as Therapy in Diabetic Neuropathic Pain","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2010-11","conditions":"Painful Diabetic Neuropathy","enrollment":332},{"nctId":"NCT00957372","phase":"PHASE3","title":"Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2004-12","conditions":"Partial Epilepsy","enrollment":253},{"nctId":"NCT01124097","phase":"PHASE3","title":"Eslicarbazepine Acetate as Therapy in Post-Herpetic Neuralgia","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2010-09","conditions":"Post Herpetic Neuralgia","enrollment":240},{"nctId":"NCT02021461","phase":"PHASE2","title":"Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2012-12","conditions":"Epilepsy","enrollment":38},{"nctId":"NCT01824602","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2006-02","conditions":"BIPOLAR I DISORDER","enrollment":38},{"nctId":"NCT01822678","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2005-12","conditions":"Bipolar I Disorder","enrollment":161},{"nctId":"NCT01825837","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2006-03","conditions":"Bipolar I Disorder","enrollment":104},{"nctId":"NCT01878578","phase":"PHASE1","title":"The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients","status":"TERMINATED","sponsor":"Bial - Portela C S.A.","startDate":"2002-11","conditions":"Epilepsy","enrollment":4},{"nctId":"NCT01587339","phase":"","title":"Systematic Review: Retigabine for Adjunctive Therapy in Partial Epilepsy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Epilepsy","enrollment":6498},{"nctId":"NCT01820585","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Fibromyalgia","enrollment":528},{"nctId":"NCT01820559","phase":"PHASE2","title":"Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2009-04","conditions":"Migraine","enrollment":452}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":6,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Zebinix","genericName":"Zebinix","companyName":"Centre Hospitalier Saint Joseph Saint Luc de Lyon","companyId":"centre-hospitalier-saint-joseph-saint-luc-de-lyon","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Zebinix, also known as Eslicarbazepine acetate, is an anticonvulsant medication used to treat partial-onset seizures in epilepsy. It works by blocking the sodium channel alpha subunit, a mechanism that is classified as a small molecule blocker.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}